Company news

Immunovant, Inc. news in 2025

Immunovant, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Immunovant Announces Pricing of $550 Million Common Stock Financing

December 10, 2025

Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025

November 9, 2025

Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

October 26, 2025

Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

September 2, 2025

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025

August 10, 2025

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025

May 28, 2025

Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

April 20, 2025

Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

March 18, 2025

Immunovant to Host Investor Webcast at 8: 00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

March 17, 2025

Immunovant Reports Financial Results for the Quarter Ended December 31, 2024

February 5, 2025

Immunovant Announces $450 Million Private Placement

January 12, 2025

Calls in 2025

Decks in 2025